SCHEMBL6701729

SCHEMBL6701729

Cc1ccc(-c2nc(NC(=N)N)nc3ccccc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.57
KDM4E B2RXH2 8/20 0.54
ALDH1A1 P00352 8/20 0.54
MAPT P10636 6/20 0.52
GAA P10253 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
NUDT1 P36639 1/20 0.52
HPGD P15428 4/20 0.47
GLA P06280 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RAB9A P51151 2/20 0.44
MAPK1 P28482 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SCN9A Q15858 1/20 0.44
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693501 0.90 MAPT (0.64) ADORA2AKDM4EALDH1A1MAPTGAA
SCHEMBL6695252 0.87 KDM4E (0.54) ADORA2AKDM4EALDH1A1MAPTGAA
SCHEMBL6699506 0.86 GAA (0.52) KDM4EALDH1A1MAPTGAAMEN1
SCHEMBL6693271 0.86 MAPT (0.52) ADORA2AKDM4EALDH1A1MAPTGAA
SCHEMBL6695597 0.86 MAPT (0.62) ADORA2AKDM4EALDH1A1MAPTGAA
SCHEMBL6695891 0.86 KMT2A (0.49) ADORA2AKDM4EALDH1A1MAPTGAA
SCHEMBL6695246 0.85 KDM4E (0.65) KDM4EALDH1A1MAPTGAAMEN1
SCHEMBL6695082 0.82 KDM4E (0.46) KDM4EALDH1A1MAPTGAAMEN1
SCHEMBL6695182 0.82 HSP90AB1 (0.61) KDM4EALDH1A1MAPTGAAMEN1
SCHEMBL11706420 0.81 MAPT (0.79) ADORA2AKDM4EALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP disclosed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 ADORA2A 1399/4885KDM4E 4437/4885ALDH1A1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.